GreenLight Biosciences, Samsung Biologics partner up to develop Covid vaccine candidate
Subject to regulatory approval, CDMO will produce mRNA vaccine on a commercial scale
GreenLight Biosciences, a biotech company, and Samsung Biologics, a contract development and manufacturing organization (CDMO), have announced a partnership agreement in which Samsung Biologics will manufacture GreenLight’s mRNA Covid-19 vaccine candidate.
The goal of the collaboration is to speed up production of GreenLight’s Covid-19 vaccine candidate for Phase III clinical trials and, subject to regulatory approval, commercial sales. The deal will leverage GreenLight’s existing manufacturing process, with technology transfer from GreenLight to Samsung beginning immediately.
“We are delighted to partner with GreenLight to leverage our expertise in manufacturing a messenger RNA Covid-19 vaccine candidate to better serve patients in lower income countries,” says John Rim, CEO of Samsung Biologics. “This collaboration demonstrates a major milestone for Samsung Biologics, as we will commence our expanded capabilities and operations to provide one-stop end-to-end messenger RNA production, from drug substance to aseptic fill-finish to commercial release, all from a single site.
